弥漫性大 B 细胞淋巴瘤中 t(14;18)的临床影响。

Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma.

机构信息

Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan 030013, China;

出版信息

Chin J Cancer Res. 2011 Jun;23(2):160-4. doi: 10.1007/s11670-011-0160-x.

DOI:10.1007/s11670-011-0160-x

PMID:23482616

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3587538/

Abstract

OBJECTIVE

Recent studies have suggested that t(14;18) is present in a significant proportion of diffuse large B-cell lymphomas (DLBCLs). However, the prognostic significance of this translocation and its relationship with BCL-2 protein expression remains controversial. Our study aimed to investigate the predictive power of t(14;18) and BCL-2 protein expression in the prognosis of DLBCLs.

METHODS

Biopsy specimens from 106 DLBCLs were analyzed using interphase fluorescence in situ hybridization (FISH). Immunophenotypic analysis of CD20, CD3, CD10, BCL-6, MUM1 and BCL-2 was performed by immunohistochemistry. SPSS 13.0 software was used for statistical analysis.

RESULTS

The t(14;18) was identified in 27 of 106 cases (25.5%). The percentages of tumor cells expressing CD10, BCL-6, MUM1 and BCL-2 were 21.7%, 26.4%, 56.6% and 73.6%, respectively. The presence of this translocation was significantly correlated with the expression of CD10 and immunophenotypic subtype (p<0.001). No association was observed between BCL-2 protein expression and the presence of t(14;18). Multivariate analysis confirmed that both t(14;18) and BCL-2 expression were significantly associated with survival. Moreover, patients with t(14;18) had worse prognosis, compared with those with BCL-2 expression (for overall survival: hazard ratio, 4.235; 95%CI, 2.153-8.329, p<0.001 vs. hazard ration, 2.743; 95%CI, 1.262-5.962, p=0.011).

CONCLUSIONS

The t(14;18) is a useful prognostic tool for the evaluation of DLBCL immunophenotype and prognosis. The prognosis of GCB (germinal centre-like B cell) DLBCL patients should be made with the consideration of the presence of this translocation, and the detection of t(14;18) should be included as a routine diagnostic test in these cases.

摘要

目的

最近的研究表明，t（14;18）存在于相当一部分弥漫性大 B 细胞淋巴瘤（DLBCL）中。然而，这种易位的预后意义及其与 BCL-2 蛋白表达的关系仍存在争议。我们的研究旨在探讨 t（14;18）和 BCL-2 蛋白表达在 DLBCL 预后中的预测能力。

方法

使用间期荧光原位杂交（FISH）分析 106 例 DLBCL 活检标本。通过免疫组化检测 CD20、CD3、CD10、BCL-6、MUM1 和 BCL-2 的免疫表型。使用 SPSS 13.0 软件进行统计分析。

结果

在 106 例病例中，有 27 例（25.5%）检测到 t（14;18）。肿瘤细胞表达 CD10、BCL-6、MUM1 和 BCL-2 的百分比分别为 21.7%、26.4%、56.6%和 73.6%。这种易位的存在与 CD10 的表达和免疫表型亚型显著相关（p<0.001）。BCL-2 蛋白表达与 t（14;18）的存在之间没有关联。多变量分析证实，t（14;18）和 BCL-2 表达均与生存显著相关。此外，与 BCL-2 表达的患者相比，t（14;18）的患者预后更差（总生存期：危险比，4.235；95%CI，2.153-8.329，p<0.001 与危险比，2.743；95%CI，1.262-5.962，p=0.011）。